Shares

22 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2023

Aug 14, 2023

SELL
$3.75 - $20.05 $56 - $300
-15 Reduced 0.09%
16,750 $316,000
Q1 2023

May 15, 2023

BUY
$3.67 - $4.92 $55 - $73
15 Added 0.09%
16,765 $64,000
Q4 2022

Feb 21, 2023

SELL
$4.55 - $6.31 $859 - $1,192
-189 Reduced 1.12%
16,750 $83,000
Q3 2022

Nov 14, 2022

BUY
$4.48 - $6.47 $846 - $1,222
189 Added 1.13%
16,939 $81,000
Q2 2022

Aug 04, 2022

BUY
$3.15 - $5.76 $44,572 - $81,504
14,150 Added 544.23%
16,750 $75,000
Q1 2022

May 09, 2022

SELL
$4.26 - $7.48 $225 - $396
-53 Reduced 2.0%
2,600 $12,000
Q4 2021

Feb 03, 2022

SELL
$4.75 - $7.5 $304 - $480
-64 Reduced 2.36%
2,653 $20,000
Q3 2021

Nov 15, 2021

BUY
$5.02 - $6.59 $4,487 - $5,891
894 Added 49.04%
2,717 $16,000
Q2 2021

Aug 13, 2021

BUY
$5.79 - $8.6 $422 - $627
73 Added 4.17%
1,823 $12,000
Q1 2021

May 14, 2021

BUY
$6.5 - $10.53 $11,375 - $18,427
1,750 New
1,750 $14,000
Q2 2020

Aug 14, 2020

SELL
$3.32 - $5.34 $886 - $1,425
-267 Closed
0 $0
Q1 2020

May 08, 2020

BUY
$2.12 - $6.8 $267 - $856
126 Added 89.36%
267 $1,000
Q4 2019

Feb 13, 2020

SELL
$2.25 - $5.8 $2,427 - $6,258
-1,079 Reduced 88.44%
141 $1,000
Q3 2019

Nov 12, 2019

BUY
$2.22 - $3.39 $2,228 - $3,403
1,004 Added 464.81%
1,220 $3,000
Q2 2019

Aug 12, 2019

SELL
$1.8 - $3.3 $3,745 - $6,867
-2,081 Reduced 90.6%
216 $0
Q1 2019

May 10, 2019

BUY
$2.41 - $5.91 $715 - $1,755
297 Added 14.85%
2,297 $7,000
Q4 2018

Feb 12, 2019

SELL
$3.94 - $9.7 $374 - $921
-95 Reduced 4.53%
2,000 $10,000
Q3 2018

Nov 01, 2018

BUY
$8.6 - $11.26 $817 - $1,069
95 Added 4.75%
2,095 $20,000
Q1 2018

May 14, 2018

BUY
$6.7 - $12.95 $13,400 - $25,900
2,000 New
2,000 $21,000
Q4 2017

Jan 31, 2018

SELL
$5.07 - $7.92 $55 - $87
-11 Closed
0 $0
Q3 2017

Nov 07, 2017

SELL
$5.4 - $8.47 $340 - $533
-63 Reduced 85.14%
11 $0
Q2 2017

Aug 10, 2017

BUY
N/A
74
74 $1,000

Others Institutions Holding IMGN

About ImmunoGen, Inc.


  • Ticker IMGN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 220,712,992
  • Description
  • ImmunoGen, Inc., a clinical-stage biotechnology company, develops antibody-drug conjugate (ADC) therapies to treat cancer. The company's product candidates include mirvetuximab soravtansine, an ADC targeting folate-receptor alpha (FRa), which is in Phase III clinical trial for the treatment of platinum-resistant ovarian cancer; and Pivekimab sun...
More about IMGN
Track This Portfolio

Track Northwestern Mutual Wealth Management CO Portfolio

Follow Northwestern Mutual Wealth Management CO and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northwestern Mutual Wealth Management CO, based on Form 13F filings with the SEC.

News

Stay updated on Northwestern Mutual Wealth Management CO with notifications on news.